Abstract
The aim of this study was to determine if lonidamine (LND) supplementation to single-agent epirubicin (EPI) could reverse anthracycline resistance in patients with metastatic breast cancer. 45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i.v.) bolus every 3 weeks. Patients who progressed were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2 and 450 mg on days 3-5. Among the 40 evaluable patients, 6 complete responses (CR) and 14 partial responses (PR) were achieved with EPI treatment alone for an overall response rate of 50%. The median duration of response was 6.5 months. Among the 25 patients treated with EPI+LND, 5 PR (21% of 24 evaluable patients) were observed with a median duration of response of 7 months. The median survival in patients receiving both treatments was 20 months. The survival for all patients was 18 months. The survival of patients receiving LND was not significantly longer than for the other patients. Myelotoxicity was the most common side-effect followed by alopecia, nausea and vomiting, and stomatitis. LND-related toxic effects were mild-to-moderate epigastralgia and myalgia. Anthracycline-related toxicity was the same in the two treatment groups. This study indicates that LND may circumvent clinical resistance to EPI without altering the pattern or severity of the toxicity of this anthracycline. Continued investigation of the clinical modulation of EPI resistance by LND in breast cancer is warranted, hopefully in patients with known multidrug resistance status.
| Original language | English |
|---|---|
| Pages (from-to) | 1611-1614 |
| Number of pages | 4 |
| Journal | European Journal of Cancer |
| Volume | 31 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- breast cancer
- chemotherapy
- epirubicin
- lonidamine
- multidrug resistance
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Hematology
Cite this
Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer. / Lopez, M.; Vici, P.; Di Lauro, L.; Paoletti, G.; Gionfra, T.; Conti, F.; Carpano, S.; Pignatti, F.; Giannarelli, D.
In: European Journal of Cancer, Vol. 31, No. 10, 1995, p. 1611-1614.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer
AU - Lopez, M.
AU - Vici, P.
AU - Di Lauro, L.
AU - Paoletti, G.
AU - Gionfra, T.
AU - Conti, F.
AU - Carpano, S.
AU - Pignatti, F.
AU - Giannarelli, D.
PY - 1995
Y1 - 1995
N2 - The aim of this study was to determine if lonidamine (LND) supplementation to single-agent epirubicin (EPI) could reverse anthracycline resistance in patients with metastatic breast cancer. 45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i.v.) bolus every 3 weeks. Patients who progressed were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2 and 450 mg on days 3-5. Among the 40 evaluable patients, 6 complete responses (CR) and 14 partial responses (PR) were achieved with EPI treatment alone for an overall response rate of 50%. The median duration of response was 6.5 months. Among the 25 patients treated with EPI+LND, 5 PR (21% of 24 evaluable patients) were observed with a median duration of response of 7 months. The median survival in patients receiving both treatments was 20 months. The survival for all patients was 18 months. The survival of patients receiving LND was not significantly longer than for the other patients. Myelotoxicity was the most common side-effect followed by alopecia, nausea and vomiting, and stomatitis. LND-related toxic effects were mild-to-moderate epigastralgia and myalgia. Anthracycline-related toxicity was the same in the two treatment groups. This study indicates that LND may circumvent clinical resistance to EPI without altering the pattern or severity of the toxicity of this anthracycline. Continued investigation of the clinical modulation of EPI resistance by LND in breast cancer is warranted, hopefully in patients with known multidrug resistance status.
AB - The aim of this study was to determine if lonidamine (LND) supplementation to single-agent epirubicin (EPI) could reverse anthracycline resistance in patients with metastatic breast cancer. 45 patients with metastatic breast cancer were treated with EPI 120 mg/m2 by intravenous (i.v.) bolus every 3 weeks. Patients who progressed were given the same chemotherapy regimen on day 4 in combination with oral LND, 150 mg on day 1, 300 mg on day 2 and 450 mg on days 3-5. Among the 40 evaluable patients, 6 complete responses (CR) and 14 partial responses (PR) were achieved with EPI treatment alone for an overall response rate of 50%. The median duration of response was 6.5 months. Among the 25 patients treated with EPI+LND, 5 PR (21% of 24 evaluable patients) were observed with a median duration of response of 7 months. The median survival in patients receiving both treatments was 20 months. The survival for all patients was 18 months. The survival of patients receiving LND was not significantly longer than for the other patients. Myelotoxicity was the most common side-effect followed by alopecia, nausea and vomiting, and stomatitis. LND-related toxic effects were mild-to-moderate epigastralgia and myalgia. Anthracycline-related toxicity was the same in the two treatment groups. This study indicates that LND may circumvent clinical resistance to EPI without altering the pattern or severity of the toxicity of this anthracycline. Continued investigation of the clinical modulation of EPI resistance by LND in breast cancer is warranted, hopefully in patients with known multidrug resistance status.
KW - breast cancer
KW - chemotherapy
KW - epirubicin
KW - lonidamine
KW - multidrug resistance
UR - http://www.scopus.com/inward/record.url?scp=0028866197&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028866197&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(95)00200-3
DO - 10.1016/0959-8049(95)00200-3
M3 - Article
C2 - 7488410
AN - SCOPUS:0028866197
VL - 31
SP - 1611
EP - 1614
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 10
ER -